If nothing else, it puts BP on notice that they ar

If nothing else, it puts BP on notice that they are not the only avenue to getting Brilacidin (IBD) to commercialization. Never hurts to have competing sources of capital vying for a treasured drug platform. Besides value, it also puts the timeline on a quicker pace because if BP wants to continue to drag their heels, they may end up with squat.